These data indicate that the intrinsically fluorescenttetravalent TetraFHER2-vcMMAE conjugate, by promoting aggregation-dependentendocytosis of HER2, serves as a highly selective and efficient drugcarrier for targeted treatment of HER2+ breast cancer cells. This evidence concerns the gene ERBB2 and breast cancer.